ESTRO Brachytherapy for Prostate Cancer 2018

What is your preferred management for a patient aged 66 years presenting with an IPSS of 19, PSA of 13.6, Gleason score 4+4 prostate cancer which is stage T3a on MR staging? He has no significant co-morbidities

A. Radical prostatectomy B. Active surveillance C. External beam IMRT to 78Gy with ADT D. LDR seed brachytherapy E. External beam IMRT + HDR boost

www.responseware.eu – ID: BT2018